M1 Modulatory TAK-091 Improves Cognition in Parkinson Disease, Study Shows

A New Hope for ParkinsonS Cognition?

For patients with Parkinson’s disease (PD) who struggle with cognitive decline, a glimmer of hope emerged from a recent phase 2 clinical trial. The study, published in JAMA Neurology, investigated TAK-071, an investigational drug that acts as an M1 positive allosteric modulator, targeting a key neurotransmitter involved in thinking adn memory.

while TAK-071 did not significantly impact gait variability, a primary endpoint, the drug demonstrated a promising effect on cognition. After six weeks of treatment, participants showed a statistically critically important improvement in their cognitive composite score, favoring TAK-071 compared to a placebo.

“Currently, only AChEIs are approved to treat mild to moderate Parkinson disease dementia (PDD), and several studies have not shown benefit in patients with PD-MCI, for which there are no approved pharmacological therapies,” noted Dr. Niraj Shanbhag, lead author of the study and a medical director in clinical development at Takeda. “In our study, TAK-071 demonstrated efficacy in a population in which more than 90% of participants had PD-MCI. Given its mechanism of action and the growing understanding of the continuum of cognitive impairment in PD, TAK-071 could have beneficial effects in patients with PD-MCI and early PDD, as well as in other conditions in which cholinergic loss likely contributes to cognitive deficits, such as Alzheimer disease and schizophrenia.”

How TAK-071 Works

TAK-071’s potential lies in its ability to enhance acetylcholine neurotransmission in the neocortex, a brain region heavily involved in cognitive functions.By boosting acetylcholine activity, the drug aims to improve attention, memory, and other cognitive processes often impaired in PD.

“TAK-071 was estimated to improve attentional control of gait primarily via augmenting acetylcholine neurotransmission in the neocortex, where M1 receptors are widely distributed,” explained Dr. Shanbhag. “Cholinergic signaling in other regions, such as the brainstem pedunculopontine nucleus–thalamus complex, has also been associated with various aspects of gait and balance in PD.It is indeed possible that targeting acetylcholine receptor subtypes that are more predominant in these regions—such as nicotinic α4β2 receptors57—may prove beneficial for falls in PD.”

Future Directions

While these findings are promising, larger, more diverse clinical trials are needed to confirm TAK-071’s effectiveness and safety for PD patients. Further research will also investigate the drug’s potential in other conditions linked to cholinergic dysfunction, such as Alzheimer’s disease.

This study offers a ray of hope for the millions of people living with PD and cognitive impairment. The development of effective treatments for cognitive decline in PD remains a crucial area of research, and TAK-071 represents a potential breakthrough in this fight.

What other conditions besides Parkinson’s disease could potentially benefit from TAK-071’s mechanism of action?

Hope on the Horizon for Parkinson’s Patients

Can TAK-071 Revitalize Cognitive Function in PD patients?

Interviewer (I): we are thrilled to welcome Dr. Niraj Shanbhag, a medical director in clinical development at Takeda, who led a recent study on TAK-071, a promising drug for cognitive decline in Parkinson’s patients. Welcome, Dr.Shanbhag!

Dr. Niraj Shanbhag (DNS): Thank you for having me. I’m excited to share more about our findings on TAK-071.

TAK-071’s Promise in Phase 2 trials

: Could you tell us about the phase 2 clinical trial’s results for TAK-071 in Parkinson’s disease patients with cognitive impairment?: Certainly! Our trial, published in JAMA Neurology, assessed TAK-071, an investigational drug acting as an M1 positive allosteric modulator. While it didn’t significantly impact gait variability, it demonstrated a promising effect on cognition. Patients showed a statistically notable enhancement in their cognitive composite score after six weeks of treatment, with a notable 90% of participants having Parkinson’s disease mild cognitive impairment (PD-MCI).: That’s indeed encouraging.How does TAK-071 work to achieve these cognitive improvements?

TAK-071’s Mechanism of Action

: TAK-071 enhances acetylcholine neurotransmission in the neocortex, a brain region critical for cognitive functions. By boosting acetylcholine activity, it aims to improve attention, memory, and other cognitive processes often impaired in PD. We estimate it improves attentional control of gait primarily via augmenting acetylcholine neurotransmission in the neocortex, where M1 receptors are widespread.: Engaging! Given this mechanism, could TAK-071 potentially benefit other conditions characterized by cholinergic loss?

Potential Applications Beyond Parkinson’s

: Yes, TAK-071’s mechanism of action suggests it could have beneficial effects in other conditions where cholinergic loss contributes to cognitive deficits, such as Alzheimer’s disease and schizophrenia. Though, more research is needed to confirm this.: We all hope so. What are the next steps for TAK-071 after these promising phase 2 results?

Future Directions for TAK-071

: Larger,more diverse clinical trials are crucial to confirm TAK-071’s effectiveness and safety in parkinson’s patients. Further research will also investigate its potential in other conditions like Alzheimer’s disease. We’re optimistic about TAK-071’s potential to become a breakthrough treatment for cognitive decline in PD and other neurological disorders.: Dr. shanbhag, thank you for giving us hope and shedding light on the promising potential of TAK-071. Our readers eagerly anticipate the results of these upcoming trials!

DNS: Thank you for having me. I couldn’t agree more; there’s still much work to be done, and hopefully, we’ll soon see a positive impact on the lives of millions with PD and cognitive impairment.